Bolivia and the Andean Community: CAN Harmonisation versus National Approval

1. Key takeaways

Bolivia is a member of the Andean Community (Comunidad Andina, CAN), and CAN has an integration-decision foundation for harmonising health product registration requirements. However, regional harmonisation does not replace national approval: Bolivia reviews devices independently under its own Manual para Registro Sanitario de Dispositivos Médicos, and Section 1.7.2 of the manual adopts the GHTF classification rules rather than any single CAN decision. GRZAN’s assessment is that the practical value of the CAN framework in Bolivia lies in aligning classification and technical language — reducing interpretation cost — and not in the portability of approval outcomes.

The CAN framework is worth understanding even though it cannot be cited. The Community has adopted integration decisions harmonising requirements for health product registration across its member states, and those decisions have shaped the vocabulary — classification families, dossier concepts, authority roles — that regulators across the region share. That shared vocabulary is precisely what makes neighbouring classification arguments legible to AGEMED reviewers: the manual may be national, but the technical dialect it is written in has regional roots, and applicants who speak that dialect fluently spend less time in translation of the metaphorical kind.

2. Legal basis

The citation stack is deliberately national. Ley N° 1737 of December 17, 1996, Article 2, supplies the statutory basis for sanitary control of health products; Decreto Supremo N° 26873 structures the unified national supply system within which public procurement of devices operates; and Sections 1.2 and 1.7.2 of the manual define scope and the classification logic. No CAN integration decision appears in the stack, which is itself the operative message of this page.

Decreto Supremo N° 26873, governing the unified national supply system, adds a procurement dimension to the analysis. Public purchasers in Bolivia buy against the national sanitary registration, not against any regional instrument, so the commercial value of a Bolivian approval is not diluted by regional membership — but neither is it extended by it. A device registered in Colombia or Peru has no procurement standing in Bolivia until it holds its own registration, which keeps the national file as the only commercially meaningful unit of compliance.

3. Expert insights

Insight 1: regional harmonisation takes effect only through national transposition. CAN decisions require transposition into domestic rules by each member state before they produce direct effect. The vehicle for Bolivian device rules remains the national manual to this day, so citing a CAN decision as the legal basis of a submission is procedurally ineffective.

Insight 2: the GHTF rules are themselves a product of regional convergence. Section 1.7.2 adopts all 16 GHTF classification rules, sharing the same classification logic as other countries in the region. The benefit is operational: where a product has already been classified in Colombia or Peru, that classification argument has reference value in Bolivia and can reduce interpretation cost significantly.

The GHTF adoption in Section 1.7.2 also simplifies multi-country programmes. All 16 classification rules are the same rules used across much of Latin America, so a classification rationale drafted once — device description, intended use, contact duration, energy application — can be restated for Bolivia with minimal rework. The restatement, not the original, is what AGEMED reviews, and the restatement must cite the manual’s own provisions rather than a foreign authority’s decision.

Insight 3: regulatory capacity is uneven across the region, and the weight of a reference is decided by the receiving authority. Within CAN, the Colombian INVIMA and the Peruvian DIGEMID have more developed systems than Bolivia’s AGEMED. Neighbouring approvals are therefore often used by AGEMED as reference, but the weight given varies by product and is decided at AGEMED’s discretion, and it cannot be written into commitments to customers.

4. Practical recommendations

1. Reuse neighbouring-country classification arguments as supporting material in the Bolivian dossier, but restate them under Section 1.7 of the manual.
2. Do not cite CAN decisions as the legal basis; the legal basis remains Ley N° 1737, D.S. N° 25235, and the manual.
3. Where Colombian or Peruvian registrations already exist, list them explicitly in the dossier as reference information, not as a recognition claim.

The distinction between reference information and recognition claim is not stylistic. A dossier that presents neighbouring approvals as reference invites the reviewer to use them as context; a dossier that presents them as entitlement invites the reviewer to correct the applicant’s legal theory, which costs goodwill and time. Drafting the framing correctly at submission is a zero-cost decision with measurable downstream effect.

Finally, record outcomes. When AGEMED accepts or discounts reference material, the treatment is visible in the file’s progress, and recording it builds an evidence base for future submissions. Over a portfolio, these records show how much weight reference approvals actually carry for each device family — knowledge that no text provides and that only accumulates through disciplined filing practice.

A note on drafting discipline completes the picture. Because the legal basis stack is national, the dossier’s regulatory summary should cite Ley N° 1737, the applicable supreme decree, and the manual with their full references, and reserve any regional context for a clearly labelled supporting section. Files that blur the two invite the reviewer to spend review time disentangling them; files that separate them let the reviewer find the national basis in seconds. The cost difference is nil; the impression difference is not.

5. Verification checklist

• □ Confirm the legal basis of the Bolivian dossier consists of national instruments
• □ Confirm the classification argument is restated under the GHTF rules of Section 1.7.2
• □ Confirm neighbouring-country approval documents are included as reference material
• □ Confirm no CAN decision is cited as the basis of the submission
• □ Confirm the treatment of reference material by AGEMED is recorded

GRZAN registration support. GRZAN provides medical device registration support in Bolivia for manufacturers, importers, and authorized representatives, including regional regulatory positioning and dossier legal-basis drafting. For project inquiries, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.